| 2.62 0.03 (1.16%) | 02-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.13 | 1-year : | 3.66 |
| Resists | First : | 2.68 | Second : | 3.13 |
| Pivot price | 2.19  |
|||
| Supports | First : | 2.2 | Second : | 1.9 |
| MAs | MA(5) : | 2.47 |
MA(20) : | 2.19 |
| MA(100) : | 2.06 |
MA(250) : | 1.97 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.4 |
D(3) : | 82.9 |
| RSI | RSI(14): 70.2 |
|||
| 52-week | High : | 2.74 | Low : | 1.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NKTX ] has closed below upper band by 4.7%. Bollinger Bands are 96.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.65 | 2.65 - 2.66 |
| Low: | 2.46 - 2.48 | 2.48 - 2.49 |
| Close: | 2.6 - 2.62 | 2.62 - 2.64 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Fri, 27 Feb 2026
Autoimmune cell therapy firm Nkarta lines up two March investor talks - Stock Titan
Tue, 20 Jan 2026
Nkarta CEO Hastings sells $53,915 in NKTX stock - Investing.com
Tue, 20 Jan 2026
Nkarta (NKTX) president Nadir sells $11,693 in shares - Investing.com
Thu, 04 Dec 2025
We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Tue, 02 Dec 2025
Nkarta to Participate in Evercore Healthcare Conference - GlobeNewswire
Sat, 22 Nov 2025
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 6,540 (K) |
| Shares Short P.Month | 6,020 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -26.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -1.9 |
| PEG Ratio | 0 |
| Price to Book value | 0.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|